Naz Rahman
Stock Analyst at Maxim Group
(0.43)
# 4,003
Out of 4,944 analysts
37
Total ratings
21.88%
Success rate
-27.3%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | n/a | $1.46 | - | 1 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiates: Buy | $17 | $6.37 | +166.88% | 1 | Apr 2, 2025 | |
| SLXN Silexion Therapeutics | Maintains: Buy | $135 → $75 | $7.40 | +913.51% | 2 | Mar 20, 2025 | |
| SCPH scPharmaceuticals | Maintains: Buy | $20 → $12 | $4.78 | +151.05% | 3 | Mar 20, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $120 → $70 | $41.27 | +69.61% | 5 | Feb 7, 2025 | |
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $1.25 | - | 2 | Dec 16, 2024 | |
| CING Cingulate | Upgrades: Buy | n/a | $3.68 | - | 4 | Nov 20, 2024 | |
| PALI Palisade Bio | Maintains: Buy | $23 → $8 | $0.81 | +886.68% | 7 | Nov 13, 2024 | |
| PRFX PainReform | Downgrades: Hold | n/a | $1.45 | - | 2 | Oct 24, 2024 | |
| ASRT Assertio Holdings | Initiates: Buy | $3 | $0.81 | +269.32% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $140 | $7.18 | +1,849.86% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $395.92 | - | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.23 | - | 3 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $2.29 | +118.34% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $10.70 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.40 | +150.00% | 1 | Feb 25, 2022 |
Galmed Pharmaceuticals
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.46
Upside: -
Nuvectis Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $17
Current: $6.37
Upside: +166.88%
Silexion Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $135 → $75
Current: $7.40
Upside: +913.51%
scPharmaceuticals
Mar 20, 2025
Maintains: Buy
Price Target: $20 → $12
Current: $4.78
Upside: +151.05%
Viking Therapeutics
Feb 7, 2025
Maintains: Buy
Price Target: $120 → $70
Current: $41.27
Upside: +69.61%
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.25
Upside: -
Cingulate
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $3.68
Upside: -
Palisade Bio
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $0.81
Upside: +886.68%
PainReform
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.45
Upside: -
Assertio Holdings
Jul 26, 2024
Initiates: Buy
Price Target: $3
Current: $0.81
Upside: +269.32%
Mar 15, 2024
Maintains: Buy
Price Target: $525 → $140
Current: $7.18
Upside: +1,849.86%
Jan 31, 2024
Downgrades: Hold
Price Target: n/a
Current: $395.92
Upside: -
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.23
Upside: -
Aug 9, 2023
Initiates: Buy
Price Target: $5
Current: $2.29
Upside: +118.34%
May 9, 2022
Downgrades: Hold
Price Target: n/a
Current: $10.70
Upside: -
Feb 25, 2022
Initiates: Buy
Price Target: $6
Current: $2.40
Upside: +150.00%